Steven E Nissen MD
Preventive Cardiology
Professor of Medicine, Cleveland Cl College of Medicine/Case West Res
Join to View Full Profile
9500 Euclid AveCleveland, OH 44195
Phone+1 800-223-2273
Fax+1 216-445-6855
Dr. Nissen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Steven Nissen is a cardiologist in Cleveland, OH and is affiliated with Cleveland Clinic. He received his medical degree from University of Michigan Medical School and has been in practice 39 years. He specializes in preventive cardiology and is experienced in general cardiology, lipid disorders, preventive cardiology, hypertension, and coronary artery disease. He has more than 500 publications and over 90,000 citations.
Education & Training
University of Kentucky College of MedicineFellowship, Cardiovascular Disease, 1981 - 1983
University of Michigan Medical SchoolClass of 1978
Certifications & Licensure
OH State Medical License 1992 - 2026
CA State Medical License 1980 - 1993
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2004-2014
- Northern Ohio Live Castle Connolly, 2006-2009
- Whos Who in Medicine and Healthcare Marquis Whos Who
Clinical Trials
- Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia Start of enrollment: 2014 Oct 30
- The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis Start of enrollment: 2017 Jan 01
- Supplements, Placebo, or Rosuvastatin Study Start of enrollment: 2021 Apr 23
Publications & Presentations
PubMed
- 1 citationsAssociation of testosterone-induced increase in neutrophil and monocyte counts with thromboembolic events: The TRAVERSE trial.Thiago Gagliano-Jucá, Karol M Pencina, Yili V Shang, Thomas G Travison, A Michael Lincoff
American Heart Journal. 2025-10-01 - Macrovascular and microvascular outcomes of metabolic surgery versus GLP-1 receptor agonists in patients with diabetes and obesity.Hamlet Gasoyan, Mohammad Hesam Alavi, Alexander Zajichek, Nicholas J Casacchia, Abdullah Al Jabri
Nature Medicine. 2025-09-16 - Long-Term Favorable Cardiac Remodeling in Obstructive Hypertrophic Cardiomyopathy Patients Treated With Mavacamten for up to 128 Weeks: Insights From the VALOR-HCM Trial.Milind Y Desai, Yuichiro Okushi, Kathy Wolski, Jeffrey B Geske, Anjali Tiku Owens
JACC. Cardiovascular Imaging. 2025-09-15
Journal Articles
- Coronary Revascularization StrategiesSteven E Nissen, Faisal G Bakaeen, JAMA
- Effect of C-reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients with High-Risk Vascular DiseaseSteven E Nissen, Jeffrey S Riesmeyer, JAMA Cardiology
- Original Investigation Effect of Evolocumab on Coronary Plaque CompositionSteven E Nissen, Ransi Somaratne, Rishi Puri, Christie M Ballantyne, ScienceDirect
- Join now to see all
Authored Content
- Coronary Revascularization StrategiesJuly 2020
- Effect of C-reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients with High-Risk Vascular DiseaseJuly 2020
- Effect of C-reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients with High-Risk Vascular DiseaseJuly 2020
- Effect of C-reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients with High-Risk Vascular DiseaseJuly 2020
- ADCY9 Genetic Variants and Cardiovascular Outcomes with Evacetrapib in Patients with High-Risk Vascular DiseaseJuly 2018
- 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical TrialsMarch 2017
- Join now to see all
Press Mentions
Weight-Loss Surgery Outperforms GLP-1 Drugs for Diabetes and Obesity, Study FindsSeptember 19th, 2025- Weight-Loss Surgery Outperforms GLP-1 Drugs, Study ArguesSeptember 19th, 2025
- Weight-Loss Surgery Shows Stronger 10-Year Health Benefits Than Popular Meds, Study FindsSeptember 17th, 2025
- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
